Literature DB >> 196800

Antibodies against cytomegalovirus-induced early antigens (CMV-EA) in immunosuppressed renal-allograft recipients.

T H The, H K Andersen, E S Spencer, G Klein.   

Abstract

Antibodies against cytomegalovirus-specific early antigens (CMV-EA) were followed in sera, obtained from fifteen immunosuppressed renal-allograft recipients. Eight patients (sixty-two sera) showed seroconversion 47--137 days post-transplantation. Five patients (forty sera) with CMV antibodies at the moment of renal implantation all showed CMV-EA antibody rises. Two patients remained seronegative until 4 years after transplantation. Thus, in immunosuppressed patients, antibodies against CMV-EA remained a high titres during many years (4--8 years) after transplantation as distinct from the apparently transient nature in acutely infected previously healthy adults with CMV mononucleosis or post-perfusion syndrome. These results support the view that CMV-EA antibodies reflect an active viral proliferation in the host.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 196800      PMCID: PMC1541019     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  10 in total

1.  Virologic and clinical observations on cytomegalic inclusion disease.

Authors:  T H WELLER; J B HANSHAW
Journal:  N Engl J Med       Date:  1962-06-14       Impact factor: 91.245

2.  Cytomegalovirus neutralization by plaque reduction.

Authors:  H K Andersen
Journal:  Arch Gesamte Virusforsch       Date:  1971

3.  Clinical aspects of cytomegalovirus infection in kidney-graft recipients.

Authors:  E S Spencer
Journal:  Scand J Infect Dis       Date:  1974

Review 4.  The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I.

Authors:  T H Weller
Journal:  N Engl J Med       Date:  1971-07-22       Impact factor: 91.245

5.  Cytomegalovirus infection among renal allograft recipients.

Authors:  H K Andersen; E S Spencer
Journal:  Acta Med Scand       Date:  1969 Jul-Aug

6.  Cytomegalovirus infection after renal allotransplantation.

Authors:  J E Craighead; J B Hanshaw; C B Carpenter
Journal:  JAMA       Date:  1967-09-04       Impact factor: 56.272

7.  Cytomegalo virus--mononucleosis. Isolation of the virus and demonstration of subclinical infections after fresh blood transfusion in connection with open-heart surgery.

Authors:  L Kääriäinen; J Paloheimo; E Klemola; T Mäkelä; A Koivuniemi
Journal:  Ann Med Exp Biol Fenn       Date:  1966

8.  Recovery of cytomegalovirus from adults with neoplastic disease.

Authors:  C P Duvall; A R Casazza; P M Grimley; P P Carbone; W P Rowe
Journal:  Ann Intern Med       Date:  1966-03       Impact factor: 25.391

9.  Microbial causes of mental retardation. The role of prenatal infections with cytomegalovirus, rubella virus, and toxoplasma.

Authors:  H Stern; J C Booth; S D Elek; D G Fleck
Journal:  Lancet       Date:  1969-08-30       Impact factor: 79.321

10.  Antibody reactions to virus-specific early antigens (EA) in patients with cytomegalovirus (CMV) infection.

Authors:  T H The; G Klein; M M Langenhuysen
Journal:  Clin Exp Immunol       Date:  1974-01       Impact factor: 4.330

  10 in total
  22 in total

1.  Cell-mediated immunity to cytomegalovirus in immunocompromised patients: effect of radiation or chemotherapy.

Authors:  Y Agatsuma; P Fitzpatrick; A Kaul; R Kaul; R Kohli; A V Paves; P L Ogra
Journal:  Infect Immun       Date:  1979-10       Impact factor: 3.441

2.  Comparison of occurrence of antibodies to human cytomegalovirus as demonstrated by immunofluorescence and indirect hemagglutination techniques.

Authors:  S Michelson; N Cabau; A Boue; F Horodniceanu
Journal:  J Clin Microbiol       Date:  1979-01       Impact factor: 5.948

3.  Discordance of Epstein-Barr Virus (EBV) specific humoral and cellular immunity in patients with malignant lymphomas: elevated antibody titres and lowered in vitro lymphocyte reactivity.

Authors:  C H Ten Napel; T H The; J Van Egten-Bijker; G C de Gast; M R Halie; M M Langenhuysen
Journal:  Clin Exp Immunol       Date:  1978-12       Impact factor: 4.330

4.  Acute cytomegalovirus infection and the host immune response. II. Relationship of suppressed in vitro lymphocyte reactivity to bacterial recall antigens and mitogens with the development of cytomegalovirus-induced lymphocyte reactivity.

Authors:  C H ten Napel; T H The
Journal:  Clin Exp Immunol       Date:  1980-02       Impact factor: 4.330

5.  Comparison of the immune response to Epstein-Barr virus and cytomegalovirus in sera and synovial fluids of patients with rheumatoid arthritis.

Authors:  M Musiani; M Zerbini; S Ferri; M Plazzi; G Gentilomi; M La Placa
Journal:  Ann Rheum Dis       Date:  1987-11       Impact factor: 19.103

6.  Antibody reactivity to human and vervet cytomegalovirus early antigen(s) in sera from patients with active cytomegalovirus infections and from asymptomatic donors.

Authors:  J L Waner; S A Biano
Journal:  J Clin Microbiol       Date:  1979-01       Impact factor: 5.948

7.  IgG subclass-specific antibodies to human cytomegalovirus (HCMV)-induced early antigens.

Authors:  A Hamann; H W Doerr
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

8.  Detection of antibody to cytomegalovirus-induced early antigens and comparison with four serologic assays and presence of viruria in blood donors.

Authors:  E B Lentz; N L Dock; C A McMahon; S R Fiesthumel; C B Arnold; H V Lamberson
Journal:  J Clin Microbiol       Date:  1988-01       Impact factor: 5.948

9.  Detection of immunoglobulin M and G antibodies against cytomegalovirus early and late antigens by enzyme-linked immunosorbent assay.

Authors:  J M Middeldorp; J Jongsma; A ter Haar; J Schirm; T H The
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

10.  Detection of antibodies to pre-early nuclear antigen and immediate-early antigens in patients immunized with cytomegalovirus vaccine.

Authors:  A D Friedman; S Michelson; S A Plotkin
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.